Cargando…

The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals

Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan Africa. The seroprevalence for KSHV is high in the region, and no prophylactic vaccine against the virus is available. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortazavi, Yasaman, Lidenge, Salum J., Tran, Tara, West, John T., Wood, Charles, Tso, For Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150787/
https://www.ncbi.nlm.nih.gov/pubmed/32111001
http://dx.doi.org/10.3390/v12030256
_version_ 1783521098177970176
author Mortazavi, Yasaman
Lidenge, Salum J.
Tran, Tara
West, John T.
Wood, Charles
Tso, For Yue
author_facet Mortazavi, Yasaman
Lidenge, Salum J.
Tran, Tara
West, John T.
Wood, Charles
Tso, For Yue
author_sort Mortazavi, Yasaman
collection PubMed
description Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan Africa. The seroprevalence for KSHV is high in the region, and no prophylactic vaccine against the virus is available. In this study, we characterized the antigenic targets of KSHV-specific neutralizing antibodies (nAbs) in asymptomatic KSHV-infected individuals and KS patients with high nAbs titers. We quantified the extent to which various KSHV envelope glycoproteins (gB, ORF28, ORF68, gH, gL, gM, gN and gpK8.1) adsorbed/removed KSHV-specific nAbs from the plasma of infected individuals. Our study revealed that plasma from a majority of KSHV neutralizers recognizes multiple viral glycoproteins. Moreover, the breadth of nAbs responses against these viral glycoproteins varies among endemic KS, epidemic KS and asymptomatic KSHV-infected individuals. Importantly, among the KSHV glycoproteins, the gH/gL complex, but neither gH nor gL alone, showed the highest adsorption of KSHV-specific nAbs. This activity was detected in 80% of the KSHV-infected individuals regardless of their KS status. The findings suggest that the gH/gL complex is the predominant antigenic determinant of KSHV-specific nAbs. Therefore, gH/gL is a potential target for development of KSHV prophylactic vaccines.
format Online
Article
Text
id pubmed-7150787
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71507872020-04-20 The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals Mortazavi, Yasaman Lidenge, Salum J. Tran, Tara West, John T. Wood, Charles Tso, For Yue Viruses Article Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi’s sarcoma (KS), one of the most prevalent cancers of people living with HIV/AIDS in sub-Saharan Africa. The seroprevalence for KSHV is high in the region, and no prophylactic vaccine against the virus is available. In this study, we characterized the antigenic targets of KSHV-specific neutralizing antibodies (nAbs) in asymptomatic KSHV-infected individuals and KS patients with high nAbs titers. We quantified the extent to which various KSHV envelope glycoproteins (gB, ORF28, ORF68, gH, gL, gM, gN and gpK8.1) adsorbed/removed KSHV-specific nAbs from the plasma of infected individuals. Our study revealed that plasma from a majority of KSHV neutralizers recognizes multiple viral glycoproteins. Moreover, the breadth of nAbs responses against these viral glycoproteins varies among endemic KS, epidemic KS and asymptomatic KSHV-infected individuals. Importantly, among the KSHV glycoproteins, the gH/gL complex, but neither gH nor gL alone, showed the highest adsorption of KSHV-specific nAbs. This activity was detected in 80% of the KSHV-infected individuals regardless of their KS status. The findings suggest that the gH/gL complex is the predominant antigenic determinant of KSHV-specific nAbs. Therefore, gH/gL is a potential target for development of KSHV prophylactic vaccines. MDPI 2020-02-26 /pmc/articles/PMC7150787/ /pubmed/32111001 http://dx.doi.org/10.3390/v12030256 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mortazavi, Yasaman
Lidenge, Salum J.
Tran, Tara
West, John T.
Wood, Charles
Tso, For Yue
The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals
title The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals
title_full The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals
title_fullStr The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals
title_full_unstemmed The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals
title_short The Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) gH/gL Complex Is the Predominant Neutralizing Antigenic Determinant in KSHV-Infected Individuals
title_sort kaposi’s sarcoma-associated herpesvirus (kshv) gh/gl complex is the predominant neutralizing antigenic determinant in kshv-infected individuals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150787/
https://www.ncbi.nlm.nih.gov/pubmed/32111001
http://dx.doi.org/10.3390/v12030256
work_keys_str_mv AT mortazaviyasaman thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT lidengesalumj thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT trantara thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT westjohnt thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT woodcharles thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT tsoforyue thekaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT mortazaviyasaman kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT lidengesalumj kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT trantara kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT westjohnt kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT woodcharles kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals
AT tsoforyue kaposissarcomaassociatedherpesviruskshvghglcomplexisthepredominantneutralizingantigenicdeterminantinkshvinfectedindividuals